Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis. (2022). Farmeconomia. Health Economics and Therapeutic Pathways, 23(1). https://doi.org/10.7175/fe.v23i1.1532